Eiger BioPharmaceutical receives interim approval to use cash collateral

By Sarah Lizee

Olympia, Wash., April 5 – Eiger BioPharmaceuticals, Inc.’s motion to access cash collateral was approved on an interim basis by the U.S. Bankruptcy Court for the Northern District of Texas, according to an order.

The motion had drawn an objection from Innovatus Life Sciences Lending Fund I, LP, the only secured lender with an interest in the collateral, but the order said all objections had either been withdrawn or overruled.

A final hearing is scheduled for April 23.

The Palo Alto, Calif.-based biopharmaceutical company filed bankruptcy on April 1 under Chapter 11 case number 24-80040.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.